And it's interesting that they put this obviously favorable announcement out potentially a couple of weeks BEFORE a decision is expected as to the Final Collaboration Agreement of which the terms are said to be " Confidential " .....and yet will include as per their below March 2021 statement " future, success-based payments "
So is it then fair to suggest that these so called " future success-based payments " which at the same time has been stated to be based around " commercial sales milestones ". Could these statements then go a long way and a lot further to underpinning an " expected future earnings profile ' ......and therefore potentially and significantly higher value of AMP 945
Remembering that their actual March announcement stated the following :-
As per ATX's announcement on 18th March 2021:-
" The final Collaboration Agreement is expected to be signed within 90 days. While the terms of the agreement are confidential,they do include future, success-based payments by Amplia to Garvan on AMP945 achieving specified clinical, regulatory and commercial sales milestones. "
So my BIGGEST question is how long this Company will be able to fly under the radar in the overall valuation stakes.......
